# Molecular Staging

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/molecular-staging

- Industry: Biotechnology
- Headquarters: New Haven, US
- Website: www.molecularstaging.com
- Total disclosed funding: $41M
- Latest round: Series D (Dec 19, 2000)
- Investors on record: 6

## About

Molecular Staging, Inc. is a biotechnology company specializing in advanced diagnostics based on life sciences technologies to detect and quantify proteins and nucleic acids for various medical conditions.Molecular Staging, Inc. was founded in 1998 and is headquartered in New Haven, US. The company focuses on developing technologies for the detection of biomarkers related to cancer and other diseases. In September 2004, Qiagen acquired Molecular Staging, Inc. The company has successfully completed 2 deals to date, with the most recent funding round being Series D, where the company raised USD 41.25 mn from investors including 3i and OrbiMed Advisors.Molecular Staging Inc. (MSI) specializes in advanced life sciences technologies that focus on the detection and quantification of proteins and nucleic acids. The company's core offerings include Rolling Circle Amplification Technology (RCAT™), which facilitates ultra-sensitive diagnostics for a range of medical conditions including cancer, infectious diseases, neuropsychiatric disorders, and autoimmune disorders. RCAT™ enhances diagnostic capabilities by amplifying the signal from minute quantities of target molecules, such as DNA, RNA, and proteins, allowing for earlier disease detection. MSI's high-coverage protein microarrays and whole-genome amplification services serve analytical needs in various healthcare markets, enabling researchers and clinicians to conduct thorough studies on multiple proteins simultaneously and renew DNA samples for ongoing testing. The company’s products are designed for extensive use in research institutions, clinical laboratories, and healthcare facilities across North America, Europe, and Asia.Molecular Staging operates within a business model that includes partnerships and collaborations with healthcare providers and research institutions. Their revenue is generated primarily through the sale of diagnostic tests and services, including their flagship RCAT™-based assays and protein microarrays. Transactions typically occur through contractual agreements with clients in the healthcare sector, where services are provided on a per-test basis or through subscription models for ongoing diagnostic needs. Pricing structures are aligned with the specialized nature of the offerings, reflecting the advanced technology and precision involved in the diagnostics. The firm engages in B2B transactions, focusing on building long-term relationships with laboratories and hospitals that require regular access to their innovative diagnostic solutions.Molecular Staging, Inc. plans to enhance its product offerings by developing new diagnostic assays leveraging their proprietary RCAT™ technology. The company aims to expand into Asian markets by 2025. The recent funding from the Series D round in September 2004 will be utilized to support these product developments and facilitate market entry strategies in targeted regions.

## Funding rounds

- Series D, Dec 19, 2000, $41M — 3i, CHL Medical Partners, Domain Associates, OrbiMed Advisors, CIBC Capital Partners, Patricia Industries

## Investors

- 3i (https://capitalatlas.ai/funds/3i) — Series D
- CHL Medical Partners (https://capitalatlas.ai/funds/chl-medical-partners) — Series D
- Domain Associates (https://capitalatlas.ai/funds/domain-associates) — Series D
- OrbiMed Advisors (https://capitalatlas.ai/funds/orbimed-advisors) — Series D
- CIBC Capital Partners — Series D
- Patricia Industries (https://capitalatlas.ai/funds/patricia-industries) — Series D